Sphingosine 1‐phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions
Top Cited Papers
- 15 July 2010
- Vol. 58 (12) , 1465-1476
- https://doi.org/10.1002/glia.21021
Abstract
Sphingolipids are a class of biologically active lipids that have a role in multiple biological processes including inflammation. Sphingolipids exert their functions by direct signaling or through signaling by their specific receptors. Phosphorylated FTY720 (FTY720P) is a sphingosine 1-phosphate (S1P) analogue that is currently in trial for treatment of multiple sclerosis (MS), which targets all S1P receptors but S1P2. To date, however, it remains unknown whether FTY720P may exert direct anti-inflammatory effects within the central nervous system (CNS), because data concerning S1P receptor expression and regulation under pathological conditions in the human brain are lacking. To investigate potential regulation of S1P receptors in the human brain during MS, we performed immunohistochemical analysis of S1P receptor 1 and 3 expression in well-characterized MS lesions. A strong increase in S1P receptor 1 and 3 expression on reactive astrocytes was detected in active and chronic inactive MS lesions. In addition, we treated primary cultures of human astrocytes with the proinflammatory cytokine tumor necrosis factor-alpha to identify the regulation of S1P1/3 on astrocytes under pathological conditions. Importantly, we demonstrate that FTY720P exerts an anti-inflammatory action on human astrocytes by limiting secretion of proinflammatory cytokines. Our data demonstrate that reactive astrocytes in MS lesions and cultured under proinflammatory conditions strongly enhance expression of S1P receptors 1 and 3. Results from this study indicate that astrocytes may act as a yet-unknown target within the CNS for the anti-inflammatory effects observed after FTY720P administration in the treatment of MS.Keywords
Funding Information
- Top Institute Pharma (T2-108-1)
- Dutch Foundation for MS Research (MS 02-358, MS 05-567, MS 05-358c)
- Solvay Pharmaceuticals B.V.
- Abbott Healthcare Products B.V.
This publication has 35 references indexed in Scilit:
- Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expressionFree Radical Biology & Medicine, 2008
- Cyclical and Dose-Dependent Responses of Adult Human Mature Oligodendrocytes to FingolimodThe American Journal of Pathology, 2008
- Immunosuppressive and Anti-angiogenic Sphingosine 1-Phosphate Receptor-1 Agonists Induce Ubiquitinylation and Proteasomal Degradation of the ReceptorJournal of Biological Chemistry, 2007
- Erythrocytes store and release sphingosine 1‐phosphate in bloodThe FASEB Journal, 2007
- BML-241 fails to display selective antagonism at the sphingosine-1-phosphate receptor, S1P3British Journal of Pharmacology, 2006
- Analysis of endogenous S1P and LPA receptor expression in CHO-K1 cellsGene, 2005
- Distinctive G protein-dependent signaling in smooth muscle by sphingosine 1-phosphate receptors S1P1and S1P2American Journal of Physiology-Cell Physiology, 2004
- The immunosuppressant FTY720 down‐regulates sphingosine 1‐phosphate G protein‐coupled receptorsThe FASEB Journal, 2004
- The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate ReceptorsJournal of Biological Chemistry, 2002
- Expression of monocyte chemoattractant protein-1 and other β-chemokines by resident glia and inflammatory cells in multiple sclerosis lesionsJournal of Neuroimmunology, 1998